Carson Wealth (CWM LLC)
ACRS icon

Carson Wealth (CWM LLC)’s Aclaris Therapeutics ACRS Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09K Buy
1,358
+978
+257% +$3.3K ﹤0.01% 5017
2025
Q4 		$1K Buy
380
+105
+38% +$265 ﹤0.01% 5162
2025
Q3 		$1K Buy
+275
New +$479 ﹤0.01% 5072
2024
Q4 		– Sell
-1
Closed – – 4876
2024
Q3 		$0 Sell
1
-267
-100% -$327 ﹤0.01% 4786
2024
Q2 		$0 Buy
268
+191
+248% +$224 ﹤0.01% 4551
2024
Q1 		$0 Buy
77
+29
+60% +$35 ﹤0.01% 4278
2023
Q4 		$0 Sell
48
-48
-50% -$146 ﹤0.01% 4095
2023
Q3 		$1K Sell
96
-492
-84% -$4.2K ﹤0.01% 3900
2023
Q2 		$6K Sell
588
-10
-2% -$90 ﹤0.01% 3317
2023
Q1 		$5K Buy
598
+582
+3,638% +$7.39K ﹤0.01% 3256
2022
Q4 		$0 Hold
16
– – ﹤0.01% 3941
2022
Q3 		$0 Hold
16
– – ﹤0.01% 3871
2022
Q2 		$0 Buy
+16
New +$224 ﹤0.01% 3741

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Carson Wealth (CWM LLC)'s ACRS Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Aclaris Therapeutics (ACRS) stake by 257% in Q1 2026, buying an estimated $3.3K and bringing the position to 1,358 shares worth $5.09K. The position accounts for ﹤0.01% of the portfolio, ranked #5017.

Carson Wealth (CWM LLC) first reported a position in ACRS in Q2 2022 and has held it in 13 quarters since. The position peaked at $6K in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Carson Wealth (CWM LLC) held 1,358 shares of Aclaris Therapeutics worth $5.09K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 978 Aclaris Therapeutics shares in Q1 2026, an estimated $3.3K.
  • Aclaris Therapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #5017 holding.
  • Carson Wealth (CWM LLC) first reported a position in Aclaris Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Carson Wealth (CWM LLC)'s Aclaris Therapeutics position peaked at $6K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.